166 related articles for article (PubMed ID: 36036788)
1. MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients.
Dong X; Chen X; Ren Y
J Clin Lab Anal; 2022 Oct; 36(10):e24650. PubMed ID: 36036788
[TBL] [Abstract][Full Text] [Related]
2. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.
Wu Z; Bi Y
J Clin Lab Anal; 2022 Feb; 36(2):e24130. PubMed ID: 34997981
[TBL] [Abstract][Full Text] [Related]
3. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
4. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA Antisense Noncoding RNA in the INK4 Locus Correlates With Risk, Severity, Inflammation and Infliximab Efficacy in Crohn's Disease.
Ge Q; Dong Y; Lin G; Cao Y
Am J Med Sci; 2019 Feb; 357(2):134-142. PubMed ID: 30665494
[TBL] [Abstract][Full Text] [Related]
6. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
Shi X; Yang W; Wang N; Zhu J
Medicine (Baltimore); 2019 Aug; 98(33):e16622. PubMed ID: 31415355
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
8. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
9. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
10. MALT1 in asthma children: A potential biomarker for monitoring exacerbation risk and Th1/Th2 imbalance-mediated inflammation.
Liu L; Gao Y; Si Y; Liu B; Liu X; Li G; Wang R
J Clin Lab Anal; 2022 May; 36(5):e24379. PubMed ID: 35353938
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
[TBL] [Abstract][Full Text] [Related]
12. [Platelet count predicts therapeutic response of infliximab for active Crohn's disease].
Shen H; Xu C; Chen C
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 45(1):81-5. PubMed ID: 27045246
[TBL] [Abstract][Full Text] [Related]
13. [Association of Breg cells and Treg cells with the clinical effects of Infliximab in the treatment of Chinese patients with Crohn's disease].
Lin QR; Xia XP; Cai XN; Hu DY; Shao XX; Xia SL; Jiang Y
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3303-3308. PubMed ID: 33202491
[No Abstract] [Full Text] [Related]
14. Aberrant blood MALT1 and its relevance with multiple organic dysfunctions, T helper cells, inflammation, and mortality risk of sepsis patients.
Wang Y; Huang Q; He F
J Clin Lab Anal; 2022 Apr; 36(4):e24331. PubMed ID: 35262976
[TBL] [Abstract][Full Text] [Related]
15. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
Wen N; Zhao N; Xu H; Zhao Y; Ma J
Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
[TBL] [Abstract][Full Text] [Related]
16. Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.
Kim MJ; Lee WY; Choe YH
Gut Liver; 2015 May; 9(3):370-80. PubMed ID: 25071071
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Dickkopf-1 with Inflammation in Crohn Disease.
Kim MJ; Choe YH
Indian Pediatr; 2019 Nov; 56(11):929-932. PubMed ID: 31729323
[TBL] [Abstract][Full Text] [Related]
18. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
19. [IL-17 and IL23 expression as a predictor of response to infliximab treatment in Crohn's disease].
Zhang X; Hu J; Suo L; Yang Z; Xu T; Zhang Y
Zhonghua Nei Ke Za Zhi; 2015 Nov; 54(11):940-4. PubMed ID: 26922821
[TBL] [Abstract][Full Text] [Related]
20. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
